Heart Health
   
Triglyceride-lowering effect of omega -3 LC-polyunsaturated fatty acids
Fish Oils and Atherosclerosis
Fish Oils Reduce Heart Disease Risk in Diabetic Women
GISSI Study
 
Triglyceride-lowering effect of omega -3 LC-polyunsaturated fatty acids
 
Author
:
Weber P, Raederstorff D
Address
:
F. Hoffmann-La Roche Ltd., Vitamins and Fine Chemicals Division, Basel, Switzerland. peter.weber@roche.com
Source
:
Nutr Metab Cardiovasc Dis 2000 Feb;10(1):28-37
Abstract :
There is increasing evidence that serum triglycerides are a significant and independent risk factor for CVD. The aim of this report is to review recent literature pertinent to the triglyceride-lowering effect of omega-3 long chain polyunsaturated fatty acids (LCPUFA). Animal data are not considered because they are difficult to extrapolate to the human situation. A large body of evidence derived from epidemiological studies and clinical trials has consistently demonstrated that this effect is dose-dependent and can be achieved by diet.
     
   
The smallest amount of omega-3 LC-PUFA needed to significantly lower serum triglycerides appears to be approximately 1 g/day as provided by a fish diet. Use of fish oil administering as little as 0.21 g EPA and 0.12 g DHA per day significantly lowered serum triglycerides in hyperlipidemics. In normolipidemics, a daily intake of 0.17 g EPA and 0.11 g DHA, given as a fish oil supplement, induced a non-significant reduction of 22%. These findings must be considered as preliminary and warrant further research. Intake of omega-3 LC-PUFA is frequently reported to modestly increase LDL cholesterol. However, in normo- or slightly hyperlipidemic individuals who received omega-3 LC-PUFA for 4 months or longer, changes of LDL cholesterol were not significantly different from a placebo group. Both EPA and DHA lower serum triglycerides, but they may have a differential effect on lipoproteins. Intake of omega-3 LC-PUFA in the amount mentioned above is safe.
back to top
 
Fish Oils and Atherosclerosis
 
A recent study has investigated the beneficial effects of fish oil supplementation and atherosclerosis. A randomized, double-blind, placebo-controlled clinical trial involved 162 patients with confirmed atherosclerosis. Half the patients were given 6 grams of fish oils per
day for three months while the other half were given 6 grams per day of placebo capsules containing a fatty acid composition resembling that of the average European diet. After three months the dosages were reduced to 3 grams/day for a further 21 months. Angiograms were taken at the start of the trial and at the end of the two-year study period. At the end of the
treatment twice as many of the patients in the fish oil group (16) showed regression of their atherosclerotic deposits when compared to the placebo group. Three patients in the placebo group suffered a nonfatal heart attack during the 2-year period as compared to only one in the fish oil group. Seven patients in the placebo group had a cardiovascular event (heart attack or stroke) as compared to only two in the fish oil group. The researchers conclude that fish oil supplementation may be beneficial for atherosclerosis patients and is safe and well-tolerated.

Reference:
von Schacky, Clemens, et al. The effect of dietary omega-3 fatty acids on coronaryatherosclerosis. Annals of Internal Medicine, Vol. 130, April 6, 1999, pp. 554-62 Co sponsor:Pronova A.S
back to top
 
Fish Oils Reduce Heart Disease Risk in Diabetic Women
 
04/01/03- Eating fish regularly reduced the risk of heart disease in diabetic women by as much as 64 percent, according to an American study out today.

"We found that women with type 2 diabetes who ate more fish had significantly lower risk of coronary heart disease and total death than those who rarely ate fish," said Dr Frank B. Hu, lead author and associate professor of nutrition and epidemiology at the Harvard School of Public Health in Boston.

His findings support previous research that has found fish consumption to reduce the risk of heart disease in a largely healthy population. But this is the first study to look at the relationship among diabetic patients, who have a very high risk of heart disease.

National health associations usually recommend that adults, except pregnant women, eat two servings of fish a week. The researchers suggest that for those with, or at high risk of cardiovascular disease (CVD), supplementing fish in the diet with fish oil capsules may be advisable in consultation with a doctor.

Omega-3 fatty acids from fish have been shown to reduce the risk of irregular heartbeats that can lead to sudden death, decrease blood triglyceride levels, improve the functions of blood vessels and reduce blood clot formation – all important factors in reducing risk for heart
disease among diabetics.

However there is little prior evidence confirming that diabetics who eat fish can gain the same benefits as people without diabetes who eat fish, Hu said, writing in the rapid access issue of Circulation, the American Heart Association journal. The researchers were also concerned that fish oil might worsen control of blood sugar among diabetic patients.

Hu and colleagues analyzed data from women with diabetes participating in the Nurses' Health Study (lifestyle and medical history data on more than 121,000 female nurses). They found 5,103 women had reported type 2 diabetes at any time from 1976-94. Women with a history of heart disease, stroke or cancer reported on the 1980 questionnaire (when diet was first assessed) or before they were excluded.

The women were divided into five categories according to how often they ate fish: less than once a month, one to three times a month, once a week, two to four times a week, and five or more times a week.

Between 1980-96, the researchers documented 362 cases of heart disease. They found that diabetic women who ate fish at least once a month were older, slightly heavier, typically did not smoke, tended to have hypertension and high cholesterol, and took multivitamin and vitamin E supplements. Those who ate more fish also ate more fruits and vegetables but ate less red and processed meats.

Compared with diabetic women who seldom ate fish (less than once a month), the risk of developing heart disease was reduced on average by 30 percent in those who ate fish one to three times a month, 40 percent for those who ate it once a week, 36 percent in those who ate fish two to four times a week, and 64 percent in those who ate fish five or more times a week. Higher fish consumption was also associated with a significantly lower death rate.

Hu suggested that the association between higher fish consumption in diabetic women and better heart health can also be extended to diabetic men based on similar findings in studies of healthier men and women.

However he admitted that the study was limited because it was not a randomized clinical trial. "Thus, the benefits we observed for fish may be due to other dietary and lifestyle factors related to fish intake," he said. Even so, Hu argued that their findings are solid because of their "careful adjustment for many important cardiovascular risk factors."

The team concluded that regular fish consumption should be considered as part of a healthy diet for diabetes management, with at least two servings weekly for individual patients. Fatty fish such as mackerel, lake trout, herring, sardines, albacore tuna and salmon are high in omega-3 fatty acids.

In an accompanying editorial, Dr Scott M. Grundy, director of the Center for Human Nutrition at the University of Texas Southwestern Medical Center at Dallas, said Hu’s research supports previous studies on omega-3 fatty acids. However, he urged that clinical trials of omega-3 fatty acids after a heart attack be conducted to determine if they can reduce coronary deaths in the short term.

In the 8 February issue of The Lancet, researchers reported that Omega-3 fatty acids apparently reduced the build up of atherosclerosis and helped to stabilize the health in stroke patients who are at high risk of atherosclerotic plaques rupturing or forming clots.

http://www.nutraingredients.com/news/news.asp?id=6736
back to top
 
GISSI Study
 
Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI)-Prevenzione Trial.

Author: Franzosi MG, Brunetti M, Marchioli R, Marfisi RM, Tognoni G, Valagussa F.

Source: Pharmacoeconomics. 2001;19(4):411-20

OBJECTIVE: To estimate the cost effectiveness of treatment with n-3 polyunsaturated fatty acids (PUFA) for secondary prevention after myocardial infarction (MI).

DESIGN AND SETTING: The cost-effectiveness analysis of n-3 PUFA treatment after MI was based on morbidity and mortality data and the use of resources obtained prospectively during the 3.5 year follow-up period of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI)-Prevenzione study. The cost-effectiveness analysis took into account the
incremental number of life-years gained and the incremental costs for hospital admissions, diagnostic tests and drugs, applying a 5% discount rate. The value for money of n-3 PUFA treatment was assessed using the cost-effectiveness ratio and the number needed to treat (NNT) approach.

PERSPECTIVE: Third-party payer.

MAIN OUTCOME MEASURES AND RESULTS: The incremental cost-effectiveness ratio for n-3 PUFA in the basecase scenario was 24,603 euro (EUR, 1999 values) per life-year gained (95% confidence interval: 22,646 to 26,930). Sensitivity analysis included the analysis of extremes, producing estimates varying from EUR15,721 to EUR52,524 per life-year
gained. 172 patients would need to be treated per year with n-3 PUFA, at an annual cost of EUR68,000, in order to save 1 patient. This is comparable with the NNT value, and associated annual cost for simvastatin, but less costly than that for pravastatin.

CONCLUSIONS: The cost effectiveness of long term treatment with n-3 PUFA is comparable with other drugs recently introduced in the routine care of secondary prevention after MI. Since the clinical benefit provided by n-3 PUFA is additive, this therapy should be added to the established routine practice, with additive costs.
back to top
 
<<HOME
 
 
 
Heart Health
Brain Health
Immune Function
Joints
  Migraine
  Metabolism
Childhood & Pregnancy
  Omega 3 Fatty Acids & Your Health
  Activ Flow & Cardiovascular Health
Activ Flow &
Omega 3
   
  多吃鱼,保心脏
  考生补脑,鱼油不可少
  脂肪代谢,靠深海鱼
 
 
 
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
Royal Omega International Pte Ltd
10 Jalan Besar #15-02, Sim Lim Tower, Singapore 208787
®Copyright 2007, Royal Omega Pte Ltd. Designed & Powered by
Exxelnet Solution